MarketMoodz
Life sciences lab real estate rebound offers both opportunity and risk for investors
Life sciences lab real estate is showing tentative life after a period of demand pullbacks tied to NIH funding shifts. Vacancy across the top markets rose to 27.4% in Q1 2026, with Boston and the San Francisco Bay Area over 30%, but construction activity has cooled to its lowest level since 2017 as VC funding stabilizes. The recovery is evolving, bringing both upside and risk for investors.
Key Takeaways
- Aggregate vacancy across the 10 largest life sciences markets rose to 27.4% in Q1 2026, up from 25.7% a year earlier.
- Boston and the San Francisco Bay Area posted vacancies above 30%.
- H2 2025 saw the strongest venture-capital investment in life sciences since 2022, signaling fresh liquidity.
- Space under construction is at its lowest since 2017, limiting new supply.
- JLL forecasts availability could fall to ~20% by 2030 as supply exits outpace absorption, with about 19 million sq ft potentially shifting to other uses.
People Involved
- Travis McCreadyJLL Life Sciences Lead
Entities Involved
- JLLReal estate advisory firm focusing on life sciences markets
- GenentechBiotech company investing in Basel HQ campus
- National Institutes of Health (NIH)U.S. government health research agency; context for funding changes
MarketMoodz Analysis
The market backdrop is a mix of tight supply discipline and cautious demand. With vacancies still high in key markets, investors should look to property types that can adapt to evolving lab needs—such as refurbished or repurposed spaces that can accommodate AI, automation, and data-centric workloads—while watching absorption trends in the next 12-24 months.
Historically, bioscience real estate swung on government funding cycles and science breakthroughs. The most recent rebound mirrors a post-pandemic era of stabilization where VC funding flows and construction slowdowns converge to compress cap rates in top markets, even as lagging Class B/C assets face more persistent headwinds.
Key developments to watch include how AI-driven lab design shifts space requirements, the pace of cap-rate normalization as absorption improves, and the degree to which large tenants and universities lock in long-term leases or pursue aggressive redevelopment strategies. Also monitor NIH budget trends and the Basel expansion at Genentech for signals on continued demand.
Source: Original Article